BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL; TSX: BCT) announced on September 14, 2026 that its independent Data Safety Monitoring Board (DSMB) has issued its seventh consecutive positive recommendation to continue the company's pivotal Phase 3 Bria-ABC study of Bria-IMT™ plus an immune checkpoint inhibitor in patients with metastatic breast cancer. The DSMB raised no safety or clinical concerns and recommended the study proceed without modifications. The ongoing trial is being conducted under FDA Fast Track designation, reflecting the significant unmet medical need in metastatic breast cancer, a development investors in the clinical-stage biotechnology company will be watching closely.

Key Points

  • BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL; TSX: BCT) is a clinical-stage biotechnology company developing novel immunotherapies for cancer care.
  • An independent DSMB issued its seventh consecutive positive recommendation to continue the pivotal Phase 3 Bria-ABC study of Bria-IMT™ plus an immune checkpoint inhibitor.
  • The DSMB reported no safety or clinical concerns and recommended no protocol modifications; DSMB meetings occur quarterly per the study protocol.
  • Investors may be watching patient enrolment progress and interim data updates as the FDA Fast Track-designated trial advances.

DSMB Clears Bria-ABC Study for Seventh Consecutive Time With No Safety Concerns

Following its most recent review of clinical data from the Bria-ABC study (NCT06072612), the independent DSMB found no safety or other clinical concerns and recommended the trial continue without modifications. The board convenes quarterly in accordance with the study protocol. Seven uninterrupted positive recommendations represent a consistent signal of tolerability for BriaCell's immunotherapy approach, combining Bria-IMT™ with an immune checkpoint inhibitor. The release states no specific adverse events or efficacy data were disclosed as part of this announcement.

FDA Fast Track Designation Underscores Unmet Need in Metastatic Breast Cancer

The Bria-ABC Phase 3 study is being conducted under Fast Track designation granted by the US Food and Drug Administration, a status reflecting the substantial unmet medical need among patients living with metastatic breast cancer. Fast Track designation is designed to facilitate development and expedite review of therapies treating serious conditions. The designation does not guarantee regulatory approval but may allow for more frequent interactions with the FDA during the development process. The company did not disclose a projected completion date or patient enrolment figures in this announcement.

BriaCell's Broader Immunotherapy Pipeline Context

BriaCell describes itself as a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care. Beyond the Bria-ABC study, the company has disclosed separate programmes targeting other cancer types. The DSMB's repeated positive recommendations reinforce the ongoing tolerability profile observed so far for Bria-IMT™ in combination with an immune checkpoint inhibitor, though the company has not disclosed efficacy endpoints or outcomes data in connection with this particular announcement. The immediate share price impact was not clear from available public information.